Norditropin® FlexPro®

Pre-clinicalRecruiting
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Growth Hormone Deficiency in Children

Conditions

Growth Hormone Deficiency in Children, Born Small for Gestational Age

Trial Timeline

Jun 21, 2019 → Jun 30, 2031

About Norditropin® FlexPro®

Norditropin® FlexPro® is a pre-clinical stage product being developed by Novo Nordisk for Growth Hormone Deficiency in Children. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03972345. Target conditions include Growth Hormone Deficiency in Children, Born Small for Gestational Age.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT03972345Pre-clinicalRecruiting

Competing Products

20 competing products in Growth Hormone Deficiency in Children

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
HER3-DXdDaiichi SankyoPre-clinical
23
ErlotinibAstellas PharmaPhase 2
52
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
33
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
Somatropin + SomatropinEli LillyPhase 3
77
Somatropin + SomatropinEli LillyPhase 3
77
somatropin, rDNA origin, for injectionEli LillyPhase 3
77
Sterile becaplermin gel vs. sterile placebo gel treatment 1Johnson & JohnsonPre-clinical
23
ABT-414AbbViePre-clinical
23
Saizen® A + Saizen® BMerckPhase 3
77
Saizen® solution for injection (referred as Saizen®)MerckApproved
85
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3
77
Saizen + SaizenMerckApproved
85
MiransertibMerckPhase 2
52
MiransertibMerckPhase 1/2
41